

27.05.11

## ACRUX RECEIVES MARKETING APPROVAL FOR ELLAVIE™ IN SWEDEN

**Melbourne, 27 May 2011:** Acrux (ASX: ACR) announced today that the Medical Products Agency (MPA) in Sweden has granted a marketing authorisation for Ellavie™, Acrux's estradiol spray for treating menopause symptoms.

The estrogen therapy market outside the USA is valued at US\$360 million per annum. In Europe, transdermal therapies (skin patches and gels) account for approximately half of the estrogen therapy market.

Marketing applications for Ellavie are currently under review by regulatory authorities in Switzerland, South Korea and South Africa. The granting of the authorisation in Sweden allows Acrux to seek marketing approvals in other European countries under a Mutual Recognition Procedure.

"We are delighted with our first European drug approval and this now places us in a strong position to actively engage potential marketing partners for the European market." said Acrux CEO Richard Treagus.

### Contact:

Richard Treagus, CEO +61 417 520 509

### About Acrux

[www.acrux.com.au](http://www.acrux.com.au)

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.

- Acrux has two products approved for marketing in the USA, one product approved in Europe, one product in registration in the USA and Europe and further products at earlier stages of development.
- Acrux received two 2010 Governor of Victoria Export Awards, including the Victorian Export Award for Innovation Excellence.

